Bicycle Therapeutics Q4 2025 Earnings Report

Bicycle Therapeutics EPS Results

• Actual EPS: -$0.29
• Consensus EPS: -$1.00
• Beat/Miss: Beat by +$0.71
• One Year Ago EPS: N/A

Bicycle Therapeutics Revenue Results

• Actual Revenue: $47.96 million
• Expected Revenue: $7.08 million
• Beat/Miss: Beat by +$40.88 million
• YoY Revenue Growth: N/A

Bicycle Therapeutics Announcement Details

• Quarter: Q4 2025
• Date: 3/18/2026
• Time: Before Market Opens
• Conference Call Date: N/A
• Conference Call Time: N/A

Bicycle Therapeutics (NASDAQ:BCYC) plc is a clinical-stage biotechnology company specializing in the discovery and development of novel peptide therapeutics based on its proprietary bicyclic peptide platform. The company’s core technology leverages constrained peptide structures that combine the binding specificity of biologics with the favorable tissue-penetration properties of small molecules. This approach is designed to generate highly selective drug candidates with potential applications across a range of therapeutic areas, including oncology, neuroscience and immunology.

Bicycle Therapeutics maintains a diversified pipeline of internally developed programs as well as collaborations with leading pharmaceutical partners. Its oncology portfolio includes targeted agents aimed at tumor-associated receptors and tumor-penetrating ligands designed to deliver therapeutic payloads. In parallel, the company is advancing candidates in neuroscience and immuno-oncology, seeking to address high-unmet-need conditions. Bicycle’s programs are being evaluated in preclinical and early clinical studies, and the company has established research collaborations with several global biopharmaceutical organizations to accelerate the clinical development of its lead molecules.

Headquartered in Cambridge, UK, Bicycle Therapeutics has expanded its presence with operations in the United States to support its growing clinical activities and partnerships. The company is led by an experienced management team with deep expertise in peptide chemistry, translational research and drug development. By integrating its proprietary platform with strategic alliances, Bicycle Therapeutics aims to advance a new class of precision medicines capable of reaching challenging therapeutic targets with improved safety and efficacy profiles.